Immu-24. Glioblastoma Enriched Glycosphingolipids Modulate The Function Of Human Inkt Cells
Morgan Coombs,Tyrone Dowdy,Md Masud Alam,Guzal Khayrullina,Vibhuti Joshi,Seketoulie Keretsu,Jinkyu Jung,Ayaka Hara,Emily Steffke,Laila Latifi,Hye Kim,Jo Spurgeon,Nargis Malik,John Hancock,Kelsey Smith,Jenny Gumperz,Mioara Larion,Masaki Terabe
DOI: https://doi.org/10.1093/neuonc/noae165.0617
2024-11-29
Neuro-Oncology
Abstract:Glioblastoma is an aggressive primary brain tumor highly resistant to currently available immunotherapies. A deeper understanding of its underlying immunoregulatory mechanisms is paramount to developing future immunotherapeutic treatments. Invariant natural killer T (iNKT) cells are unconventional T cells that recognize lipid antigens presented by an MHC-like molecule called CD1d. Although iNKT cells have been shown to regulate tumor immunity in other cancer types, their role in glioblastoma is not well characterized. Given the lipid-rich nature of the brain and the unique metabolic activity of glioblastoma cells, we hypothesized that interactions between glioblastoma and iNKT cells through glioblastoma-produced lipids could contribute to the immunosuppressive nature of the disease. We report multiple lipid species enriched in aggressive human glioblastoma stem-like cell (GSC) lines that activate human iNKT cells and modulate their functions. Lipidomic LC-MS analysis of GSCs, low-grade glioma stem-like cell lines, and normal human astrocytes revealed various glycosphingolipid species, including sulfatides, highly enriched in the GSCs. Multiple enriched sulfatide species, when presented by CD1d, were recognized by and activated iNKT cells in a dose-dependent manner. Additionally, cytokine analysis of stimulated human PBMC-derived iNKT cells demonstrated that the enriched sulfatides did not induce Th1 cytokine production, but rather many non-Th1 cytokines that potentially counteract Th1-type immune responses. This modulation of iNKT cell function by glioblastoma-enriched glycosphingolipids may contribute to the immunosuppression of glioblastoma and could highlight sulfatide production as a potential therapeutic target for glioblastoma treatment.
oncology,clinical neurology